Glenmark Pharmaceuticals has informed that it enclosed a press release titled ‘Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40mg/20 mL (2 mg/mL), 150mg/30mL (5 mg/mL), and 200mg/20 mL (10 mg/mL) Single-Dose Vials’.
The above information is a part of company’s filings submitted to BSE.